Skip to main content
. Author manuscript; available in PMC: 2018 Aug 9.
Published in final edited form as: Cephalalgia. 2017 Apr 4;37(8):780–794. doi: 10.1177/0333102417702120

Figure 2.

Figure 2.

CYM51317, a short-acting KOR antagonist, blocks BLS-induced periorbital or hindpaw cutaneous allodynia. (a), (b): BLS-induced periorbital (a) and hindpaw (b) allodynia in sumatriptan pre-exposed rats was blocked by systemic administration of CYM51317 (20 mg/kg, p.o.) at 1 h prior to each BLS episode. ***p < 0.001 vs. baseline (BL). Group sizes are shown on the figure. (c), (d): Group comparisons of Area Over the Curve (AOC) for periorbital (c) and hindpaw (d) allodynia demonstrate that administration of CYM51317 (20 mg/kg, p.o.) prior to each BLS episode significantly blocked BLS-induced tactile hypersensitivity. **p < 0.01, ***p < 0.001. Data represent mean ± SEM. Statistics performed using two-way ANOVA with Dunnett’s multiple comparisons post-hoc test for (a) and (b); and one-way ANOVA followed by Fisher’s LSD post-hoc test for (c) and (d).